Nine Masts Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Nine Masts Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-97,478	Closed	-$3.92M	–	178
2026 Q1	$3.92M	Buy	+97,478	New	+$2.1M	0.57%	27

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Nine Masts Capital's APLS Position: Q2 2026 in Review

Nine Masts Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 97,478 shares — an estimated $3.92M sold.

Nine Masts Capital first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $3.92M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Nine Masts Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 97,478 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.92M.
Nine Masts Capital first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's Apellis Pharmaceuticals position peaked at $3.92M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.